NEW YORK, April 15 (GenomeWeb News) - Xantos Biomedicine today announced an agreement to use Atugen's atuRNAi short interfering RNAi compounds to validate an angiogenic target in animal studies.
Atugen said that its atuRNAi gene-silencing approach has already been "successfully applied to validate and modulate disease targets in liver diseases and several animal models for cancer."
Financial details of the collaboration were not disclosed.